Cyclophilin inhibitors

  • Flisiak R
  • Parfieniuk-Kowerda A
  • 34


    Mendeley users who have this article in their library.
  • 2


    Citations of this article.


The percentage of patients chronically infected with hepatitis C virus (HCV) who have reached sustained antiviral response has increased since the introduction of the pegylated interferon-alpha (pIFNa) and ribavirin (RBV) treatment. However, the current standard pIFNa/RBV therapy not only has a low success rate (about 50%) but is often associated with serious side effects. Thus, there is an urgent need for the development of new anti-HCV agents. Cyclophilin (Cyp) inhibitors are among the most promising of the new anti-HCV agents under development. Recent clinical studies demonstrate that Cyp inhibitors are potent anti-HCV drugs, with a novel mechanism of action and efficacy profiles that make them attractive candidates for combination with current and future HCV treatments. © 2009 Elsevier Inc. All rights reserved.

Author-supplied keywords

  • Alisporivir
  • Cyclosporine
  • Debio-025
  • Host targeting antivirals
  • Liver
  • NIM-811
  • SCY-635
  • Viral hepatitis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free